🧬 SinoBioData Academic Portal
🏛️ Indexed Academic JournalOriginal: 中国新药杂志

Chinese Journal of New Drugs

Premier Chinese Biomedical Journal indexed in SinoBioData: Chinese Journal of New Drugs (中国新药杂志).

Total Research Papers: 200
Access: 100% Free Open Access
Browse by Publication Year & VolumeReset All Filters ✕

Published Research PapersFiltered: Year 2025 • Vol. 47

Showing 3 of 200 peer-reviewed papers with full Graphical Abstracts.

Original ResearchVol. 47, Issue 2 • pp. 450-462DOI: 10.1007/s12345-024-01234-5

Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis

Authors: Zhang Wei, Li Na, Wang Fang, Chen Yu, Liu Yang

Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.

Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Graphical Abstract
Original ResearchVol. 47, Issue 2 • pp. 450-462DOI: 10.1007/s12345-024-01234-5

Adverse Drug Reactions Related to COVID-19 Vaccination: A Systematic Review and Meta-Analysis

Authors: Zhang Wei, Li Na, Wang Fang, Chen Yu, Liu Yang

Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and characteristics of ADRs associated with COVID-19 vaccines. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to March 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates. Results: A total of 45 studies involving 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4). Local reactions were most common (78.5%), followed by systemic reactions (45.2%). The most frequent local reaction was injection site pain (70.2%), and the most frequent systemic reactions were fatigue (34.5%), headache (28.7%), and myalgia (22.3%). Serious ADRs were rare (0.08%). The incidence of ADRs was higher in younger adults and females. mRNA vaccines had a higher incidence of systemic reactions compared to viral vector vaccines. Conclusion: COVID-19 vaccines are generally safe, with mostly mild and transient ADRs. The findings support the continued use of COVID-19 vaccines to combat the pandemic.

Adverse Drug Reactions Related to COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Graphical Abstract
Original ResearchVol. 47, Issue 3 • pp. 512-525DOI: pub_80__articleID_242

Pharmaceutical Care in China: A Systematic Review of Current Status and Future Directions

Authors: Y. Zhang, L. Wang, H. Li, J. Chen

Pharmaceutical care has evolved globally as a patient-centered practice, yet its implementation in China faces unique challenges. This systematic review synthesizes evidence from 2010 to 2024 to evaluate the current status, barriers, and outcomes of pharmaceutical care in Chinese healthcare settings. A comprehensive search of PubMed, CNKI, and Wanfang databases identified 1,245 articles, of which 38 met inclusion criteria. Findings reveal that pharmaceutical care in China is predominantly hospital-based, focusing on medication reconciliation, therapeutic drug monitoring, and patient education. However, significant barriers include workforce shortages, lack of standardized protocols, and limited integration with primary care. Despite these challenges, studies demonstrate improved medication adherence, reduced adverse drug events, and enhanced patient satisfaction. The review proposes a framework for advancing pharmaceutical care through policy reforms, interprofessional collaboration, and digital health technologies. Future directions emphasize community-based services and personalized medicine to align with global standards.

Pharmaceutical Care in China: A Systematic Review of Current Status and Future Directions
Graphical Abstract